-
Company Insights
Innovation and Patenting activity of Imugene Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Imugene Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-011 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-011 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-011 in Refractory Multiple Myeloma Drug Details: CB-011 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OnCARlytics in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OnCARlytics in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OnCARlytics in Ovarian Cancer Drug Details: onCARlytics (CF33-CD19) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OnCARlytics in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OnCARlytics in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OnCARlytics in Solid Tumor Drug Details: onCARlytics (CF33-CD19) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAXINIA in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VAXINIA in Head And Neck Cancer Drug Details: VAXINIA...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAXINIA in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VAXINIA in Gastric Cancer Drug Details: VAXINIA (CF33+hNIS) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAXINIA in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VAXINIA in Bladder Cancer Drug Details: VAXINIA (CF33+hNIS) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAXINIA in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VAXINIA in Hepatocellular Carcinoma Drug Details: VAXINIA (CF33+hNIS) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAXINIA in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VAXINIA in Solid Tumor Drug Details: VAXINIA (CF33+hNIS) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VAXINIA in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAXINIA in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VAXINIA in Kidney Cancer (Renal Cell Cancer) Drug...